DAWN - Day One Biopharmaceuticals, Inc. Stock Price, Fair Value and News

$14.35+0.56 (+4.06%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

DAWN RSI Chart

DAWN Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-7.23

Price/Sales (Trailing)

69.02

Price/Free Cashflow

-6.82

DAWN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

DAWN Fundamentals

DAWN Revenue

Revenue (TTM)

17.5M

Rev. Growth (Yr)

-93.77%

Rev. Growth (Qtr)

-34.59%

DAWN Earnings

Earnings (TTM)

-167.5M

Earnings Growth (Yr)

90.39%

Earnings Growth (Qtr)

92.94%

DAWN Price Action

Last 7 days

-2.2%

Last 30 days

-2.2%

Last 90 days

5.0%

Trailing 12 Months

-2.0%

DAWN Profitability

Return on Equity

-54.6%

Return on Assets

-41.82%

Free Cashflow Yield

-14.66%

DAWN Financial Health

Current Ratio

4.09

DAWN Investor Care

Shares Dilution (1Y)

0.90%

Diluted EPS (TTM)

-1.94

DAWN Alerts

2 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	60.5M	17.5M	0	0
2023	8.2M	53.9M	57.3M	59.6M
2022	0	0	0	4.7M
2021	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

CEO	Dr. Jeremy Bender M.B.A., Ph.D.
WEBSITE	https://dayonebio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	124

Day One Biopharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Day One Biopharmaceuticals, Inc.? What does DAWN stand for in stocks?

DAWN is the stock ticker symbol of Day One Biopharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Day One Biopharmaceuticals, Inc. (DAWN)?

As of Wed Sep 18 2024, market cap of Day One Biopharmaceuticals, Inc. is 1.21 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DAWN stock?

You can check DAWN's fair value in chart for subscribers.

Is Day One Biopharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether DAWN is over valued or under valued. Whether Day One Biopharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Day One Biopharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DAWN.

What is Day One Biopharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Sep 18 2024, DAWN's PE ratio (Price to Earnings) is -7.23 and Price to Sales (PS) ratio is 69.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DAWN PE ratio will change depending on the future growth rate expectations of investors.